Hot COVID-19
Home > News > 5th NEXTGEN CHINA 2015 - To Manufacture International High Quality Generics in Opportunities and Challenges
Industry Updates New Products Supplier News Upcoming Events business web

5th NEXTGEN CHINA 2015 - To Manufacture International High Quality Generics in Opportunities and Challenges

Hits:2646   Date: 1/21/2015
The 5th NEXTGEN CHINA 2015
-- To Manufacture International High Quality Generics in Opportunities and Challenges
Organized by: CPhI Conferences & UBM
March 25-27, 2014
Shanghai China
7 Compelling Reasons to Attend
*Delving into key trends of generics regulatory, market and technology
*Impurity research and & QbD implementation case study
*Hearing in-depth presentations from 20+ global speakers under CPhI resources
*Covering 2 Chapters: Regulation compliance and GENERICS CONSISTENCY EVALUATION and market strategy analysis along with the technology updating
*Networking with and 150+ decision makers from pharmaceutical companies
*Benefiting from case studies from leading generic pharmacy of US, EU and India
*15+ professional presentations, 2 workshops and 2+ panel discussion, getting on-spot answers to your critical business and technical challenges
Conference Background:
There are lot of opportunities for Chinese generics industry development. However, how to manufacture international high quality generics is still a key issue for manufacturers.
*How to understand GENERICS CONSISTENCY EVALUATION and how to make product meet the requirement of regulation?
*Stricter of regulation from FDA&EU, how to access to overseas market?
*How to do impurity control and dissolution rate comparison?
*How implement QbD successfully and how to do cost reduction strategies?
*How to improve equivalence to increase generics quality and drug internationalization
*Diversified development of generics market, M&A of pharmacy, strategic cooperation, generics branding, supergenerics, biosimilars and influence of CRO & CMO…
The 5th NEXTGEN CHINA 2015 will gather all resource of CPhI global and essence of past four conferences to explore topics above and showcase evolving generics landscape & solutions.
Conference Structure:
Pre-Conference Workshop (March 25, 2015)
Morning: How to do generics impurity research scientifically and reasonably combing with registration requirement
Afternoon: Application and case analysis of Quality by Design (QbD) in generics R&D and manufacture
Day One (March 26, 2015)
Regulation compliance and Generics Consistency Evaluation
Day Two (March 27, 2015)
Market strategy analysis of generics along with the techniques updates
Past Attendees of NEXTGEN:
Teva, Mylan, Sandoz, Pfizer, GSK, Boehringer-Ingelheim, AstraZeneca, Sanofi, Movartis, Merck, JNJ, Abbott, Bristol-Myers Squibb, Bayer, Roche, Dr. Reddy’s, Shanghai Pharma Group, Huhai, Hengrui, Yangtze River, Tasly, China Resources, Xian-Janssen, Qilu, Zhejiang Medicine, Wuhan Humanwell, Northeast Pharm, North China Pharmaceutical, Sinopharm, Kelun Group…
Who Should Attend?
Job Title
(Pie Chart)
Decision Makers 25%
R&D 25%
Regulatory Affairs 10%
Marketing 10%
BD 10%
QA/QC 10%
Manufacture 5%
Others 5%
Industry Sectors 
(Pie Chart)
Government/Regulatory/Association/Research 10%
Generics/Biosimilar Manufacturers 50%
Innovator Pharma Manufacturers 10%
API, Ingredient & Material Suppliers 5%
Equipment/Service/IT/PAT Suppliers 5%
Finance/Investment/VC 5%
Marketing/Consulting/Others 5%
Tel: 86-21-61573868/61573922